Abstract:The Action in Diabetes and vascular disease: preterAx and diamicoN-MR Controlled Evaluation (ADVANCE) trial was designed to assess the effects of blood pressure lowering, irrespective of initial blood pressure levels or the use of other blood pressure lowering drugs, on vascular disease in patient with type 2 diabetes [1]. In this randomized trial, 11,140 patients with type 2 diabetes, older than 55 years with other cardiovascular risk factors were randomized to a fixed dose of the ACE inhibitor (perindopril) with a thiazide-like diuretic (indapamide) and compared to placebo. All other concurrent medications except for the randomized drugs classes were allowed to continue. The primary endpoint of this trial was the composite of major macro and microvascular events. After a mean follow-up of 4.3 years, patients on the fixed dose combination of perindopril and indapamide had a mean reduction in blood pressure of 5.6/2.2 mmHg compared to placebo. The relative risk of major micro and macro vascular event was reduced by an additional 9% in this group. The separate reductions in microvascular and macrovascular events were not significant. The relative risk of death from any cardiovascular cause was reduced by 18% and all cause mortality by 14%. Thus, for every 79 patients treated one death could be avoided. Based on these data the authors conclude that a fixed dose combination of perindopril and indapamide should be recommended for all patients with type 2 diabetes, irrespective of their existing blood pressure. The question is did ADVANCE advance our knowledge? The cardiovascular benefits of ACE inhibitors in patients with type 2 diabetes are well established by multiple clinical trials. The HOPE trial showed that ramipril reduced rates of death, cardiovascular events in patients with type 2 diabetes and supported the use of ramipril in every patient with diabetes regardless of blood pressure status [2]. Additionally, the PROGRESS trial that studied the same agents as in ADVANCE, demonstrated that when a diuretic was added to an ACE inhibitor stroke incidence was reduced, but this too was related to a lower blood pressure [3]. So, should all patients with type 2 diabetes take a fixed dose combination of perindopril+indapamide or should we simply aim at lowering blood pressure to recommended goals using the best tolerated most cost effective agents? Other large clinical trials have shown that tight control of blood pressure in patients with diabetes resulted in better outcomes. Cardiovascular events were reduced by 51 % in the diabetic subgroup of the Hypertension Optimal Treatment (HOT) trial [4], a trial that randomized a dihydropyridine calcium antagonist compared to conventional treatment. In HOT the group with the lower events had a 4 mmHg lower diastolic blood pressure. In the United Kingdom Prospective Diabetes Study (UKPDS) patients who had tight control of blood pressure i.e. 10/5 mmHg lower than control, had a 24% risk reduction for any diabetes related endpoint. In UKPDS, however, no differences were observed between ACE inhibitor and β-blocker randomized patients [5]. The conclusion of these studies is that blood pressure lowering regardless of agent was similarly effective in reducing incidence of diabetic complications. To further bolster this argument in the ADVANCE trial, because of the study design, 55% of patients in placebo group were receiving perindopril at the end of the follow up however, none were allowed to receive a thazide diuretic. Thus, one could argue that like PROGRESS, where the addition of the diuretic resulted in further blood pressure lowering and a lower stroke risk, this is what we see in ADVANCE. One may come to the conclusion that the beneficial effects of the perindopril+ indapamide combination are not exclusive to this combination. Moreover, it is clear that a diuretic is needed to further lower blood pressure when an ACE inhibitor is used in such patients. Furthermore, there was no significant difference in tolerability and adherence between groups in Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial

Analysis of demands for oral medical care for 3 875 soldiers

An Analysis on Need and Demand for Dental Service in Urban Residents of Beijing

Demands Analysis on Military Qualified Health and Epidemic Prevention Personnel Cultivating

MRI of the Optic Nerves and Chiasm in Patients With Leber Hereditary Optic Neuropathy

Investigation and Analysis on Present Situation of Medical Record Administrators of Military Hospitals

Study on knowledge and demand regarding AIDS among military personnel in Shaanxi province

[Analysis on Oral Health Care Utilization and Expenditure of Residents in Beijing].

Survey on Teaching Demand on Military Health Service Commander Profession Training

Investigation and Analysis on Current Situation of Medical Record Management Department of 67 Military Hospitals

Factors Analysis of Health Status of PLA Force Personnel

Identifying Risk Factors for Dental Emergency Visits in the US Army

Prevalence of Low Back Pain among Soldiers at an Army Base.

Research on Need of Health Services and Utilization in Navy Ship Force

Report of the National Investigation of Resources for Oral Health in China.

Utilisation of Oral Health Services and Economic Burden of Oral Diseases in China.

Analysis on the demands of medical service quality of obstetrical department in maternal and child health hospital

Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial.

Epidemiological survey on oral health status of residents in a poor mountain village in yuexi,anhui province

An Investigation Into The Disease Profile And Healthcare Costs Of Inpatients Treated At A Major Oral And Maxillofacial Surgical Center

A study on the medical institutions of stomatology and dental manpower distribution in the city of Shenyang

Oral Health Survey of Elder People in Northeast of China